Caribou Biosciences (CRBU) Change in Account Payables (2020 - 2026)
Caribou Biosciences (CRBU) reported Change in Account Payables of -$2.2 million for Q1 2026, down 258.12% year-over-year from $1.4 million in Q1 2025, and down 215.69% on a QoQ basis from $1.9 million in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of Change in Account Payables data on file, last reported at -$2.2 million in Q1 2026.
- Quarterly Change in Account Payables fell 258.12% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$370000.0 (up 77.84% YoY) and the FY2025 annual result came in at $3.3 million, up 1019.21% from the prior year.
- Change in Account Payables declined to -$2.2 million in Q1 2026 per CRBU's latest filing, from $1.9 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.7 million in Q1 2024 and bottomed at -$2.4 million in Q2 2024.
- The 5-year median for Change in Account Payables is -$153000.0 (2022), against an average of -$13058.8.
- The widest annual swing landed in 2022, when Change in Account Payables sank 5275.68%; it then soared 937.99% in 2025.
- Tracing CRBU's Change in Account Payables over 5 years: stood at -$153000.0 in 2022, then surged by 577.12% to $730000.0 in 2023, then sank by 131.37% to -$229000.0 in 2024, then soared by 937.99% to $1.9 million in 2025, then tumbled by 215.69% to -$2.2 million in 2026.
- Per Business Quant, the three latest CRBU Change in Account Payables figures stand at -$2.2 million (Q1 2026), $1.9 million (Q4 2025), and $561000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | -2.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.22 Mn |
| Mar 31, 2026 | -2.22 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Sep 30, 2025 | 561,000.00 |
| Sep 30, 2025 | 561,000.00 |
| Jun 30, 2025 | -630,000.00 |
| Jun 30, 2025 | -630,000.00 |
| Mar 31, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | -229,000.00 |
| Dec 31, 2024 | -229,000.00 |
| Sep 30, 2024 | -477,000.00 |
| Sep 30, 2024 | -477,000.00 |
| Jun 30, 2024 | -2.37 Mn |
| Jun 30, 2024 | -2.37 Mn |
| Mar 31, 2024 | 2.72 Mn |
| Mar 31, 2024 | 2.72 Mn |
| Dec 31, 2023 | 730,000.00 |
| Dec 31, 2023 | 730,000.00 |
| Sep 30, 2023 | -953,000.00 |
| Sep 30, 2023 | -953,000.00 |
| Jun 30, 2023 | 540,000.00 |
| Jun 30, 2023 | 540,000.00 |
| Mar 31, 2023 | 1.50 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | -153,000.00 |
| Dec 31, 2022 | -153,000.00 |
| Sep 30, 2022 | 989,000.00 |
| Sep 30, 2022 | 989,000.00 |
| Jun 30, 2022 | -1.64 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -1.92 Mn |
| Mar 31, 2022 | -1.92 Mn |
| Dec 31, 2021 | 291,000.00 |
| Dec 31, 2021 | 291,000.00 |
| Sep 30, 2021 | -183,000.00 |
| Sep 30, 2021 | -183,000.00 |
| Jun 30, 2021 | 994,000.00 |
| Jun 30, 2021 | 994,000.00 |
| Mar 31, 2021 | 37,000.00 |
| Mar 31, 2021 | 37,000.00 |
| Dec 31, 2020 | 1.95 Mn |
| Dec 31, 2020 | 1.95 Mn |
| Sep 30, 2020 | -2.23 Mn |
| Sep 30, 2020 | -2.23 Mn |